Shots:

• Novo Nordisk plans to initiate a pivotal P-llla program to evaluate the efficacy and safety of Semaglutide (oral- 14mg- qd) vs PBO in 3-700 patients with AD with the anticipated initiation in H1’21
• The decision follows the evaluation of GLP-1 data from preclinical models- real-world evidence studies- post-hoc analysis of data from large cardiovascular outcomes trials- as well as discussions with regulatory authorities
• Semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycemic control in adults with T2D in the US- EU and Japan

 ­ Ref: Novo Nordisk | Image: Energy Watch